Call for Abstract

International Conference on Retroviruses and Novel Drugs, will be organized around the theme “Current Concepts In Retroviruses & Advanced Drug Research”

Retroviruses-2015 is comprised of 13 tracks and 69 sessions designed to offer comprehensive sessions that address current issues in Retroviruses-2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Basic molecular virology
  • Track 1-2Retrotransposons
  • Track 1-3Origin of retro elements based on reverse transcriptase
  • Track 1-4Retrovirus in invertebrates
  • Track 1-5Cell biology of virus entry into human cells
  • Track 1-6Genomic organization of the human endogenous retrovirus
  • Track 2-1Malignant Disease
  • Track 2-2Hematological diseases
  • Track 2-3Bone and joint diseases
  • Track 2-4Neurological diseases
  • Track 2-5Pulmonary diseases
  • Track 2-6Plant diseases
  • Track 3-1Cytokines and viral infections
  • Track 3-2Coat protein-mediated resistance & virus infection
  • Track 3-3Retroviral infections followed by CNS
  • Track 3-4EIAV infected lung diseases
  • Track 3-5Retroviral infection on nervous system & macrophages
  • Track 3-6Human infection and simian retroviruses
  • Track 4-1Human pathogenic viruses
  • Track 4-2Murine leukemia virus glycosylated gag and viral budding
  • Track 4-3HTLV-2 Tax2 and pathogenesis
  • Track 4-4Neuropathogenesis
  • Track 4-5Pathogenesis of Lung diseases
  • Track 4-6Influenza virology
  • Track 5-1Endogenous form of mouse mammary tumor virus
  • Track 5-2Human endogenous retrovirus
  • Track 5-3RNA synthesis and intracellular trafficking
  • Track 5-4Vetenary virology
  • Track 5-5Tumorigenesis
  • Track 6-1Cellular mechanism of HIV control and activation
  • Track 6-2Virus-induced host innate immune response.
  • Track 6-3Innate Immununity 1,Adaptive Immunity 1
  • Track 6-4Role of cellular factors in the replication of human retroviruses
  • Track 6-5C-type lectins in HIV-1 infection
  • Track 6-6Carbohydrate Antigen
  • Track 7-1Various gene therapy prospects
  • Track 7-2Viral Vectors for Human Gene Therapy
  • Track 7-3Technical hurdles
  • Track 7-4Speculative uses for gene therapy
  • Track 8-1Epigenetic changes in retroelements in cancers
  • Track 8-2Immunotheraphy
  • Track 8-3Prostate cancer
  • Track 8-4Viral oncology
  • Track 8-5Frameshift mutations
  • Track 8-6Human T-Cell Leukemia viruses
  • Track 9-1HIV-1 persistence and control of virus replication in brain
  • Track 9-2Identification and evolution of new inhibitors of HIV-1 replication
  • Track 9-3HIV infections and risk of Cardiovascular diseases in women
  • Track 9-4AIDS related pathogenesis
  • Track 9-5The immune system,HIV,and Aging
  • Track 9-6Risk of transmitting HIV
  • Track 10-1Tat associate with specific set of cellular RNA’S
  • Track 10-2Proteome analysis of the HIV-1 Gag interactome
  • Track 10-3Immunotheraphy and Naturaltheraphy
  • Track 10-4Traditional antiretrovirals phase III
  • Track 10-5Phase I Antiretrovirals
  • Track 10-6HIV vaccine research
  • Track 11-1Drug interactions and combinations
  • Track 11-2HIV 1 Antiretroviral resistance
  • Track 11-3Diagnostic tests for retroviral infections
  • Track 11-4Antiretroviral vaccine development
  • Track 11-5Development in retroviral gene therapy
  • Track 11-6Development of noval HIV integrase inhibitors
  • Track 12-1Drug therapy
  • Track 12-2Retrovirus in Human cancer
  • Track 12-3Treatment of veterinary retroviruses
  • Track 12-4Antiretroviral theraphy &resistance
  • Track 12-5AIDS research
  • Track 12-6HIV-associated neurocognitive disorders (HAND).